$3.05 Million in Sales Expected for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) This Quarter

Equities research analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will announce $3.05 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings. The lowest sales estimate is $2.17 million and the highest is $4.00 million. Syros Pharmaceuticals reported sales of $2.38 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.2%. The company is expected to announce its next quarterly earnings report on Thursday, May 6th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year sales of $12.39 million for the current financial year, with estimates ranging from $8.67 million to $16.00 million. For the next financial year, analysts forecast that the business will post sales of $14.21 million, with estimates ranging from $8.67 million to $17.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, March 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.08). Syros Pharmaceuticals had a negative return on equity of 111.54% and a negative net margin of 743.58%.

Several research firms recently issued reports on SYRS. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 24th. Alliance Global Partners reduced their target price on shares of Syros Pharmaceuticals from $18.00 to $14.00 in a report on Friday, March 5th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Syros Pharmaceuticals currently has an average rating of “Buy” and an average price target of $16.50.

Syros Pharmaceuticals stock traded down $0.32 during midday trading on Monday, hitting $6.53. The stock had a trading volume of 1,261,610 shares, compared to its average volume of 757,918. The firm’s fifty day moving average is $8.61 and its two-hundred day moving average is $9.69. The company has a market capitalization of $402.50 million, a PE ratio of -3.93 and a beta of 2.01. Syros Pharmaceuticals has a 52-week low of $6.40 and a 52-week high of $15.65. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.44.

In other Syros Pharmaceuticals news, Director Richard A. Young sold 3,750 shares of the stock in a transaction that occurred on Tuesday, February 16th. The shares were sold at an average price of $12.05, for a total transaction of $45,187.50. Following the completion of the sale, the director now directly owns 321,711 shares of the company’s stock, valued at approximately $3,876,617.55. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 14.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of SYRS. Squarepoint Ops LLC bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $107,000. Principal Financial Group Inc. bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at approximately $114,000. HighVista Strategies LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at approximately $119,000. Nisa Investment Advisors LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at approximately $141,000. Finally, LPL Financial LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at approximately $152,000.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia.

Featured Article: Elliott Wave Theory

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.